Perkembangan Terapi Kanker Prostat
DOI:
https://doi.org/10.55175/cdk.v46i8.426Keywords:
Kanker prostat, terapiAbstract
Kanker prostat termasuk keganasan yang paling sering dijumpai pada pria. Five-year survival rate untuk kanker prostat sangat tinggi. Sekitar 25-33% kanker prostat lokal yang diterapi dengan pembedahan dan radioterapi akan rekuren. Kanker prostat stadium lanjut dikategorikan menjadi non-metastatik, metastatik, dan kanker prostat resisten kastrasi. Terapi penurunan hormon androgen dan kemoterapi masih penting untuk kanker prostat stadium lanjut. Enzalutamide dan terapi terkait penurunan androgen, penghambat CYP17 abiraterone, memperbaiki radiographic progression free survival (rPFS) dan menunda saat dimulainya kemoterapi.
Prostate cancer is the most common malignancy in men. The overall 5-year survival rate for prostate cancer is very high. Approximately 25-33% of the patients with localized prostate cancer treated with surgery and radiotherapy will experience recurrence. Advanced prostate cancer is categorized into non-metastatic, metastatic, and castration-resistant prostate cancer (CRPC). Androgen deprivation therapy (ADT) and chemotherapy remain important for advanced prostate cancer. One of the ADTs, enzalutamide and treatment are related to androgen reduction, CYP17 inhibitor abiraterone, improve rPFS and delay time to initiation of chemotherapy.
Downloads
References
American Cancer Society. Prostate cancer [Internet]. 2018 [cited 2018 Sept 30]. Available from: https://www.cancer.org/cancer/prostate-cancer.html
Ellsworth PI. Prostate cancer. MedicineNet.com [Internet]. 2018 [cited 2018 Sept 30]. Available from: https://www.medicinenet.com/prostate_cancer/article.htm#prostate_cancer_facts
Peng Y, Chen Q, Gu M, Chen Y, Zhang M, Zhou J, et al. Human stromal cells in the peripheral zone of the prostate promote tumorigenesis of prostatic cancer stem cells through up-regulation of C-Kit expression. Journal of Cancer 2015;6(8):776-85.
Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S, et al. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key? Molecular Medicine Reports 2012;5:313-6.
Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 2017;35:S1-13.
GLOBOCAN 2018. International Agency for Research on Cancer [Internet]. 2018 September [cited 2018 Sept 30]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
GLOBOCAN 2018. International Agency for Research on Cancer [Internet]. 2018 September [cited 2018 Sept 30]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
Cancer.Net. Prostate cancer: Statistics [Internet]. 2005-2018 [cited 2018 Sept 30]. Available from: https://www.cancer.net/cancer-types/prostate-cancer/statistics
Cancer.Net. Prostate cancer: Risk factors and prevention [Internet]. 2018 [cited 2018 Sept 30]. Available from: https://www.cancer.net/cancer-types/prostatecancer/risk-factors-and-prevention
Shah SIA. An update on the risk factors for prostate cancer. WCRJ 2016;3(2):e711.
Haque R, Van Den Eeden SK, Wallner L, Richert-Boe K, Kallakury B, Wang R, et al. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract. 2014;8(4):e374-81.
De Nunzio C, Andriole GL, Thompson IM Jr, Freedland SJ. Smoking and prostate cancer: A systematic review. Eur Urol Focus 2015;1(1):28-38.
Ding H, Fan S, Zhang L, Hao Z, Liang C. Does prostatitis increase the risk of prostate cancer? A meta-analysis. Int J Clin Exp Med. 2017;10(3):4798-808.
Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, et al. Vasectomy and risk of aggressive prostate cancer: A 24-year follow-up study. J Clin Oncol. 2014;32:3033-8.
Cheuck L. Prostate cancer diagnosis and staging. Medscape [Internet]. 2018 Sept 27 [cited 2018 Oct 1]. Available from: https://emedicine.medscape.com/article/458011-overview#a7
NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Version 4.2018 [Internet]. 2018 [cited 2018 Oct 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer. A review. JAMA 2017;317(24):2532-42.
Cancer.Net. Prostate cancer: Diagnosis [Internet]. 2005-2018 [cited 2018 Sept 30]. Available from: https://www.cancer.net/cancer-types/prostate-cancer/diagnosis
Keyes M, Crook J, Morton G, Vigneault E, Usmani N, Morris WJ. Treatment options for localized prostate cancer. Can Fam Physician 2013;59:1269-74.
Baum N, Levy J. Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective. Postgraduate Medicine 2015;127:654-9.
Gomella LG, Singh J, Lallas C, Trabulsi EJ. Hormone therapy in the management of prostate cancer: Evidence-based approaches. Ther Adv Urol. 2010;2(4):171-81.
Auclerc G, Antoine EC, Cajfinger F, Brunet-Pommeyrol A, Agazia C, Khayat D. Management of advanced prostate cancer. The Oncologist 2000;5:36-44.
Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. European Urology 2007;51:306-14.
Boccon-Gibod L. Non-steroidal anti-androgen monotherapy of advanced prostate cancer – A reasonable option? Current opinion in Urology 1997;7:268-72.
Schellhammer PF. An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother. 2002;3(9):1313-28.
Ammannagari N, George S. Anti-androgen therapies for prostate cancer: A focused review. The American Journal of Hematology/Oncology 2015;11(2):15-9.
Greasley R, Khabazhaitajer M, Rosario DJ. A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Management and Research 2015;7:153-64.
Oudard S, Fizazi K, Sengelov L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189-97.
Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: An evidence-based review of its place in therapy. Core Evidence 2010;10:1-10.
Sipuleucel-T. Product information. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ 2016;355:i4405.
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, et al. Radium 22 dichloride for prostate cancer treatment. Drug Design, Development and Therapy 2017;11:2643-51.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-23
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
